Tumor Biology

, Volume 37, Issue 5, pp 6413–6418 | Cite as

Prognostic significance of GPC5 expression in patients with prostate cancer

Original Article

Abstract

The objective of this study was to evaluate the protein level of glypican-5 (GPC5) and its relationship with clinicopathologic significance in prostate cancer. The protein level of GPC5 in 160 prostate cancer tissues and 60 adjacent normal samples was examined by immunohistochemistry analysis, and the results were correlated with clinicopathologic parameters. The level of GPC5 in prostate cancer tissues was markedly lower than that in normal cases, especially in high-risk prostate cancer. Additionally, the low expression of GPC5 was closely associated with increased serum prostate-specific antigen (PSA), higher Gleason scores, advanced tumor stage (T3), positive lymph node metastasis, and biochemical recurrence. Moreover, GPC5 low expression was an independent prognostic factor for overall survival of patients with prostate cancer. GPC5 protein expression showed a close correlation with the tumorigenesis and tumor progression of prostate cancer, and that might be applied as a novel biomarker for the prediction of diagnosis and prognosis of prostate cancer.

Keywords

Prostate cancer GPC5 Clinicopathologic parameters Tumor biomarker 

Notes

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81402124, 81472416, and 21577097), the Chinese Academy of Science and Technology of Strategic Leading Science and Technology (B) (grant numbers XDB14040401 and XDB14010300), the Application Base and Frontier Technology Project of Tianjin (grant number 14JCQNJC10800), the Tianjin City High School Science & Technology Fund Planning Project (grant number 20130124), and the Science and Technology Fund of Tianjin Municipal Bureau of Health (grant numbers 2014KZ110 and 2015KZ109). We thank the lab members for the great assistance with the experiments and reagents.

Authors’ contributions

Zhihong Zhang and Yong Xu contributed to the conception and design of the study. Changwen Zhang, Li Wang, and Baomin Qiao contributed to the development of methodology. Changwen Zhang, E Du, and Li Li contributed to the acquisition of data (acquired and managed patients, provided facilities, etc.). Changwen Zhang, Zhifei Liu, and Zhihong Zhang contributed to the analysis and interpretation of data (e.g. statistical analysis, biostatistics, computational analysis). Changwen Zhang, Zhihong Zhang, and Yong Xu contributed to the writing, review, and/or revision of the manuscript. Changwen Zhang and Zhifei Liu contributed to the administrative, technical, or material support (i.e. reporting or organizing data, constructing databases). Zhihong Zhang and Yong Xu contributed to the study supervision.

Compliance with ethical standards

This study was approved by the Human Ethics Committee of Tianjin Medical University.

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15:e484–92.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127:679–95.CrossRefPubMedGoogle Scholar
  4. 4.
    Klotz LPT. Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. Oncology (Williston Park). 2014;28:950–C953.Google Scholar
  5. 5.
    Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–55.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    De Cat B, David G. Developmental roles of the glypicans. Semin Cell Dev Biol. 2001;12:117–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Michael J, Neat NF, Jenner M, Goff L, Ashcroft K, Burford D, et al. Localisation of a novel region of recurrent amplification in follicular lymphoma to an ∼6.8 mb region of 13q32-33. Genes Chromosom Cancer. 2001;32:236–43.CrossRefGoogle Scholar
  8. 8.
    DA Reardon JJ, Sublett JE, Burger PC, Kun LK. Multiple genomic alterations including n-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg. 2000;32:187–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Williamson D, Selfe J, Gordon T, Lu Y-J, Pritchard-Jones K, Murai K, et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 2007;67:57–65.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang C, Zhang S, Zhang D, Zhang Z, Xu Y, Liu S. A lung cancer gene gpc5 could also be crucial in breast cancer. Mol Genet Metab. 2011;103:104–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Yang XZZ, Qiu M, Hu J, Fan X, Wang J, Xu L, et al. Glypican-5 is a novel metastasis suppressor gene in non-small cell lung cancer. Cancer Lett. 2013;341:265–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhao ZHC, Liu J, Wang C, Wang Y, Cheng L. Gpc5, a tumor suppressor, is regulated by mir-620 in lung adenocarcinoma. Mol Med Rep. 2014;9:2540–6.PubMedGoogle Scholar
  13. 13.
    Li Y, Sheu C-C, Ye Y, de Andrade M, Wang L, Chang S-C, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010;11:321–30.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang C, Gao C, Xu Y, Zhang Z. Ctbp2 could promote prostate cancer cell proliferation through c-myc signaling. Gene. 2014;546:73–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RCN, Bangma CH, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57:79–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Song HH, Filmus J. The role of glypicans in mammalian development. Biochim Biophys Acta Gen Subj. 2002;1573:241–6.CrossRefGoogle Scholar
  18. 18.
    DeBaun MR, Ess J, Saunders S. Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab. 2001;72:279–86.CrossRefPubMedGoogle Scholar
  19. 19.
    Xiang YYLV, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene. 2001;20:7408–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim HXG, Borczuk AC, Busch S, Filmus J, Capurro M, Brody JS, et al. The heparan sulfate proteoglycan gpc3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol. 2003;29:694–701.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of UrologySecond Hospital of Tianjin Medical University, Tianjin Institute of UrologyTianjinChina
  2. 2.Department of UrologyTangshan People’s HospitalHebeiChina
  3. 3.Department of Obstetrical and Gynaecological SciencesSecond Hospital of Tianjin Medical UniversityTianjinChina
  4. 4.Tianjin Institute of UrologyTianjin Medical UniversityTianjinChina

Personalised recommendations